|
Bioavailability of Efavirenz Capsule Contents
(Sprinkles) Mixed with a Small Amount of Food
Compared with Intact Capsules in Healthy Adults
|
|
|
Reported by Jules Levin
1st International Workshop on HIV Pediatrics -
Cape Town, South Africa - July 17 - 18, 2009
S. Kaul, P. Ji*, M. Lu*, D. Seekins, K. L. Nguyen, T. Shangguan, D. Grasela
Bristol-Myers Squibb Research and Development, Princeton, NJ USA
This study was sponsored by Bristol-Myers Squibb
AUTHOR CONCLUSIONS
The AUC of EFV capsule contents mixed with these food vehicles was bioequivalent to the intact capsule formulation administered under fasted conditions
All treatments were generally safe and well tolerated
Grape jelly was the most palatable food vehicle
These data suggest that EFV capsule contents may be administered with a small amount (2 teaspoons) of applesauce, grape jelly, yogurt, or infant formula
![backgroud-1.gif](../images/072909/072909-4/backgroud-1.gif)
![methods-2.gif](../images/072909/072909-4/methods-2.gif)
![hands-3.gif](../images/072909/072909-4/hands-3.gif)
![pm-4.gif](../images/072909/072909-4/pm-4.gif)
![cross-5.gif](../images/072909/072909-4/cross-5.gif)
![deom-6.gif](../images/072909/072909-4/deom-6.gif)
![ABC-7.gif](../images/072909/072909-4/ABC-7.gif)
![Oral-8.gif](../images/072909/072909-4/Oral-8.gif)
![grp-9.gif](../images/072909/072909-4/grp-9.gif)
![group-10.gif](../images/072909/072909-4/group-10.gif)
![forGroup-11.gif](../images/072909/072909-4/forGroup-11.gif)
![table2-12.gif](../images/072909/072909-4/table2-12.gif)
![figure-13.gif](../images/072909/072909-4/figure-13.gif)
![Tremnt-14.gif](../images/072909/072909-4/Tremnt-14.gif)
![more-15.gif](../images/072909/072909-4/more-15.gif)
![events-16.gif](../images/072909/072909-4/events-16.gif)
REFERENCES
1. Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv. 2007;4:37-45.
2. Sustiva (efavirenz) capsules and tablets package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2009 March.
3. Sustiva (efavirenz) summary of product characteristics. Uxbridge, United Kingdom: Bristol-Myers Squibb Pharmaceuticals Ltd; 2008 August.
|
|
|
|
|
|
|